Literature DB >> 15081134

Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge.

A K Kohli1, H O Alpar.   

Abstract

The aim of this study was to investigate the effect of size and charge on the permeation of nanoparticles through the skin as the first step in designing a transdermal vaccine delivery system. Fluorescent particles ranging in size and charge were applied to the surface of full thickness pig skin in a diffusion chamber and the receptor fluid was assayed to determine permeation. Fluorescence microscopy was used to visualise the skin after experiments. The results showed that only 50 and 500 nm particles that were negatively charged were able to permeate the skin. This provides evidence of the potential of nanoparticles as delivery vectors for antigens and DNA for the purpose of transdermal vaccination protocols. The results would indicate that negative particles with sufficient charge may be ideal carriers for this purpose.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081134     DOI: 10.1016/j.ijpharm.2003.10.038

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  38 in total

1.  Nanostructured lipid carriers to enhance transdermal delivery and efficacy of diclofenac.

Authors:  Chien Ngoc Nguyen; Thi Thuy Trang Nguyen; Hanh Thuy Nguyen; Tuan Hiep Tran
Journal:  Drug Deliv Transl Res       Date:  2017-10       Impact factor: 4.617

2.  In vitro percutaneous permeation and skin accumulation of finasteride using vesicular ethosomal carriers.

Authors:  Yuefeng Rao; Feiyue Zheng; Xingguo Zhang; Jianqing Gao; Wenquan Liang
Journal:  AAPS PharmSciTech       Date:  2008-07-23       Impact factor: 3.246

3.  Nanoparticles and their interactions with the dermal barrier.

Authors:  Marc Schneider; Frank Stracke; Steffi Hansen; Ulrich F Schaefer
Journal:  Dermatoendocrinol       Date:  2009-07

4.  Topical Lyophilized Targeted Lipid Nanoparticles in the Restoration of Skin Barrier Function following Burn Wound.

Authors:  Jilong Li; Subhadip Ghatak; Mohamed S El Masry; Amitava Das; Yang Liu; Sashwati Roy; Robert J Lee; Chandan K Sen
Journal:  Mol Ther       Date:  2018-04-27       Impact factor: 11.454

5.  A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer.

Authors:  Xin-Shuai Wang; De-Jiu Kong; Tzu-Yin Lin; Xiao-Cen Li; Yoshihiro Izumiya; Xue-Zhen Ding; Li Zhang; Xiao-Chen Hu; Jun-Qiang Yang; She-Gan Gao; Kit S Lam; Yuan-Pei Li
Journal:  Acta Pharmacol Sin       Date:  2017-05-29       Impact factor: 6.150

6.  Dual Encapsulated Dacarbazine and Zinc Phthalocyanine Polymeric Nanoparticle for Photodynamic Therapy of Melanoma.

Authors:  Sara Rhaissa Rezende do Reis; Edward Helal-Neto; Aline Oliveira da Silva de Barros; Suyene Rocha Pinto; Filipe Leal Portilho; Luciana Betzler de Oliveira Siqueira; Luciana Magalhães Rebelo Alencar; Si Amar Dahoumane; Frank Alexis; Eduardo Ricci-Junior; Ralph Santos-Oliveira
Journal:  Pharm Res       Date:  2021-02-18       Impact factor: 4.200

Review 7.  Toxicity of nanomaterials.

Authors:  Shahriar Sharifi; Shahed Behzadi; Sophie Laurent; M Laird Forrest; Pieter Stroeve; Morteza Mahmoudi
Journal:  Chem Soc Rev       Date:  2011-12-14       Impact factor: 54.564

8.  Naturally occurring nanoparticles from English ivy: an alternative to metal-based nanoparticles for UV protection.

Authors:  Lijin Xia; Scott C Lenaghan; Mingjun Zhang; Zhili Zhang; Quanshui Li
Journal:  J Nanobiotechnology       Date:  2010-06-09       Impact factor: 10.435

9.  Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations.

Authors:  Suzanne M Bal; Zhi Ding; Gideon F A Kersten; Wim Jiskoot; Joke A Bouwstra
Journal:  Pharm Res       Date:  2010-06-18       Impact factor: 4.200

Review 10.  Application of nanotechnologies for improved immune response against infectious diseases in the developing world.

Authors:  Michael Look; Arunima Bandyopadhyay; Jeremy S Blum; Tarek M Fahmy
Journal:  Adv Drug Deliv Rev       Date:  2009-11-14       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.